Endocrine Response to Heart Failure

  • M. Burnier
  • B. Waeber
  • J. Nussberger
  • H. R. Brunner
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 6)


Cardiac failure is a clinical entity of various causes and severity characterized by an inability of the heart to deliver a sufficient amount of blood to meet the metabolic demands of the body at rest or during exercise. Thus, as acute or chronic heart failure develops, several compensatory mechanisms are activated to maintain an adequate perfusion to vital organs such as the brain and the heart, at the expense of other non-essential organs such as the kidneys, the gut or the muscles. The neurohumoral systems involved in the maintenance of blood pressure when heart function is failing are the same as those implicated in the regulation of blood pressure when dehydration or severe losses of blood volume occur i.e. the sympathetic nervous system, the renin-angiotensin-aldosterone system and plasma arginine vasopressin. This endocrine response results in various degrees of peripheral vasoconstriction and renal sodium retention depending on the severity of the cardiocirculatory imbalance. In advanced heart failure, however, the increase in peripheral resistance and the enhanced sodium reabsorption with subsequent volume expansion are likely to compromise myocardial function by increasing afterload as well as myocardial oxygen consumption. A vicious circle is established that will lead to further irreversible myocardial damage despite the activation of other systems with vasodilatory and natriuretic properties such as the atrial natriuretic peptide or the protaglandins. An integrated scheme demonstrating the neurohumoral consequences of heart failure is presented in Fig. 1.


Heart Failure Congestive Heart Failure Sympathetic Nervous System Atrial Natriuretic Peptide Plasma Renin Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Di Bona GF (1977) Neurogenic regulation of renal tubular sodium reabsorption. Am J Physiol 233: 173–181Google Scholar
  2. 2.
    Goldstein DS, McCarthy R, Polinsky RJ, Kopin IJ (1983) Relationship between plasma norepinephrine and sympathetic neural activity. Hypertension 5: 552–559PubMedGoogle Scholar
  3. 3.
    Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41: 233–243PubMedCrossRefGoogle Scholar
  4. 4.
    Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN (1982) Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659–1666PubMedCrossRefGoogle Scholar
  5. 5.
    Gaffney TE, Braunwald E (1963) Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 34: 320–324PubMedCrossRefGoogle Scholar
  6. 6.
    Cohn JN, Levine TB, Olivari MT, et al (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823PubMedCrossRefGoogle Scholar
  7. 7.
    Chidsey CA, Braunwald E, Morrow AG (1965) Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 39: 442–450PubMedCrossRefGoogle Scholar
  8. 8.
    Dzau VJ, Hollenberg NK, Williams GH (1983) Neurohumoral mechanisms of heart failure: role in pathogenesis, therapy, and drug tolerance. Fed Proc 42: 3162–3169PubMedGoogle Scholar
  9. 9.
    Bristow MR, Ginsburg R, Monibe W, et al (1982) Decreased catecholamine sensitivity and 1-adrenergic-receptor density in failing human heart. N Engl J Med 307: 205–211PubMedCrossRefGoogle Scholar
  10. 10.
    Chidsey CA, Braunwald E, Morrow AG, Mason DT (1963) Myocardial norepinephrine concentration in man: Effects of reserpine and of congestive heart failure. N Engl J Med 269: 653–658Google Scholar
  11. 11.
    Pierpont GL, Francis GS, DeMaster EG, Levine TB, Bolman RM, Cohn JN (1983) Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy. Am J Cardiol 52: 1033–1035PubMedCrossRefGoogle Scholar
  12. 12.
    Chidsey CA, Harrison OL, Braunwald E (1962) Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 267: 650–654PubMedCrossRefGoogle Scholar
  13. 13.
    Olivari MT, Levine TB, Cohn JN (1983) Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. J Am Coll Cardiol 2 (3): 411–417PubMedCrossRefGoogle Scholar
  14. 14.
    Eckberg DL, Drabinsky M, Braunwald E (1971) Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 285: 877–883PubMedCrossRefGoogle Scholar
  15. 15.
    Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoffer RL (1981) Short-term effects of intravenous clonidine in congestive heart failure. Clin Pharmacol Ther 30: 724–728PubMedCrossRefGoogle Scholar
  16. 16.
    Francis GS, Parks R, Cohn JN (1983) The effects of bromocriptin in patient with congestive heart failure. Am Heart J 106: 100–106PubMedCrossRefGoogle Scholar
  17. 17.
    Levine TB (1985) Role of vasodilators in the treatment of congestive heart failure. Am J Cardiol 55: 32A - 35APubMedCrossRefGoogle Scholar
  18. 18.
    Elkayam U, Le Jemtel TH, Mathur M, et al (1979) Marked early attenuation of hemodynamic effect of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol 44: 540–545PubMedCrossRefGoogle Scholar
  19. 19.
    Veterans Administration Cooperative Study (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 314: 1547–1552CrossRefGoogle Scholar
  20. 20.
    Colucci WS, Williams GH, Braunwald E (1981) Clinical, hemodynamic and neuroendocrine effects of chronic prazosin therapy for congestive heart failure. Am Heart J 102: 615–621PubMedCrossRefGoogle Scholar
  21. 21.
    Goldberg LI, Hsieh YY, Resnetov L (1977) Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Progr Cardiovasc Dis 19 (4): 327–340CrossRefGoogle Scholar
  22. 22.
    Colucci WS, Alexander RW, Williams GH, et al (1981) Decreased lymphocyte ß-adrenergicreceptor density in patients with heart failure and tolerance to the ß-adrenergic agonist pirbuterol. N Engl J Med 305: 185–190PubMedCrossRefGoogle Scholar
  23. 23.
    Rajfer SI, Anton AH, Rossen JD, Goldberg LI (1984) Beneficial hemodynamic effects of oral levodopa in heart failure. N Engl J Med 310: 1357–1362PubMedCrossRefGoogle Scholar
  24. 24.
    Fisher ML, Plotnick GD, Peters RW, Carliner NH (1986) Beta-blockers in congestive cardiomypathy. Conceptual advance or contraindication. Am J Med 80 (Suppl 2B): 59–66PubMedCrossRefGoogle Scholar
  25. 25.
    Packer M (1987) Converting enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concepts. J Cardiovasc Pharmacol 10 (S7): S83 - S87PubMedCrossRefGoogle Scholar
  26. 26.
    Deboben A, Inagami T, Ganten D (1983) Tissue renin. In: Genest J, Kuchel O, Hamet P, Cantin M (eds) Hypertension–physiopathology and treatment. McGraw-Hill, New York, pp 194–209Google Scholar
  27. 27.
    Gavras H, Kremer D, Brown JJ, et al (1975) Angiotensin-and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 89 (3): 321–332PubMedCrossRefGoogle Scholar
  28. 28.
    Turini GA, Brunner HR (1982) The role of hormones in congestive heart failure: new frontiers in therapy? Clin Sci 63: 333–338PubMedGoogle Scholar
  29. 29.
    Turini GA, Waeber B, Brunner HR (1983) The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captropril and enalapril. Eur Heart J 4 (Suppl A): 189–197PubMedGoogle Scholar
  30. 30.
    Captopril Multicenter Research Group (1983) A pacebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755–763CrossRefGoogle Scholar
  31. 31.
    The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 23: 1429–1435Google Scholar
  32. 32.
    Fyhrquist F, Hortling L, Forslund T, Laasonen L (1982) Reduction of plasma vasopressin and renin substrate in congestive heart failure during captopril treatment. From principle to practice, Biomedical Information Co, New York pp 51–62Google Scholar
  33. 33.
    Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet DG, Berl T, Schrier RW (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305: 263–266PubMedCrossRefGoogle Scholar
  34. 34.
    Bichet DG, Kortas C, Mettauer B, et al (1986) Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 29: 1188–1196PubMedCrossRefGoogle Scholar
  35. 35.
    Montani JP, Liard JF, Schoun J, Moehring JH (1980) Hemodynamic effect of exogenous and endogenous vasopressin at low concentrations in conscious dogs. Circ Res 47: 346–355PubMedGoogle Scholar
  36. 36.
    Cowley AW, Monos E, Guyton AC (1974) Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 34: 505–514PubMedGoogle Scholar
  37. 37.
    Goldsmith SR, Francis GS, Cowley AW, Goldenberg IF, Cohn JN (1986) Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8: 779–783PubMedCrossRefGoogle Scholar
  38. 38.
    Nicod P, Biollaz J, Waeber B, et al (1986) Hormonal, global and regional hemodynamic responses to a vascular antagonist of vasopressin in patients with congestive heart failure with and without hyponatremia. Br Heart J 56: 433–439PubMedCrossRefGoogle Scholar
  39. 39.
    Edwards BS, Zimmerman RS, Burnett JC (1987) Atrial natriuretic factor: physiologic actions and implications in congestive heart failure. Cardiovasc Drugs Ther 1: 89–100PubMedCrossRefGoogle Scholar
  40. 40.
    Biollaz J, Bidiville J, Diézi J, et al (1987) Site of the action of a synthetic atrial natriuretic peptide evaluated in humans. Kidney Int 32: 537–546PubMedCrossRefGoogle Scholar
  41. 41.
    Cody RJ, Atlas SA, Laragh JH, et al (1986) Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 78: 1362–1374PubMedCrossRefGoogle Scholar
  42. 42.
    Goy JJ, Waeber B, Nussberger J, et al (1988) Infusion of atrial natriuretic peptide to patients with congestive heart failure. J Cardiovasc Pharmacol (In press)Google Scholar
  43. 43.
    Tsunoda K, Mandelsohn FAO, Sexton PM, Chai SY, Hodsman GP, Johnston CI (1988) Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ Res 62: 155–161PubMedGoogle Scholar
  44. 44.
    Mauer EF (1955) The toxic effects of phenylbutazone (butazolidin): review of the literature and report of the twenty-third death following its use. N Engl J Med 253: 404–410PubMedCrossRefGoogle Scholar
  45. 45.
    Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH (1984) Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 310: 347–352Google Scholar
  46. 46.
    Liang CS, Imai N, Stone CK, Woolf PD, Kawashima S, Tuttle RR (1987) The role of endogenous opioids in congestive heart failure: effects of nalamefene on systemic and regional hemodynamic in dogs. Circulation 75 (2): 443–451PubMedCrossRefGoogle Scholar
  47. 47.
    Archelos J, Xiang JZ, Lang RE (1987) Regulation of release and function of neuropeptides in the heart. J Cardiovasc Pharmacol 10 (Suppl 12): S45 - S50PubMedCrossRefGoogle Scholar
  48. 48.
    Waeber B, Aubert JF, Corder R, et al (1988) Cardiovascular effects of neuropeptide Y. Am J Hypertension (In press)Google Scholar
  49. 49.
    Lee WH, Packer M (1986) Congestive heart failure: Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 73: 257–267Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • M. Burnier
  • B. Waeber
  • J. Nussberger
  • H. R. Brunner

There are no affiliations available

Personalised recommendations